Table 2: Summary of findings table.

Outcomes

Anticipated absolute effects*(95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Certainty of the evidence
(GRADE)

Risk with placebo or no RhIG

Risk with RhIG provision

Iso-immunization in subsequent pregnancy

13 per 1,000

10 per 1,000
(1 to 102)

OR 0.75
(0.07 to 8.42)

250
(2 RCTs)

⨁◯◯◯
VERY LOWa,b,c

Antibody formation detected six-month after initial pregnancy by indirect combs test

31 per 1,000

13 per 1,000
(2 to 103)

OR 0.41
(0.05 to 3.66)

194
(3 RCTs)

⨁◯◯◯
VERY LOWa,c

Increased fetal surveillance or fetal transfusion in subsequent pregnancy.

not pooled

not pooled

not pooled

(0 studies)

-

Neonatal morbidity (Jaundice, neonatal anemia, erythroblastosis or bilirubin encephalopathy in subsequent pregnancies)

not pooled

not pooled

not pooled

(0 studies)

-

Maternal adverse events of ant-D administration including anaphylaxis

not pooled

not pooled

not pooled

(0 studies)

-

Cost of treatment

not pooled

not pooled

not pooled

(0 studies)

-

aBoth included studies were considered as high risk of bias; bThis outcome is a surrogate for clinically relevant outcome; cThere is a wide confidence interval crossing line of no effect.